CANBRIDGE-B (01228) plans to discount approximately 14.70% of the total share issuance of 84.0336 million shares, raising approximately HK$1.99 billion net.
North Sea Kang Cheng-B (01228) announced that on February 15, 2026, the Company entered into a subscription agreement with the subscriber. As per the agreement, the Company has conditionally agreed to issue and the subscriber has conditionally agreed to subscribe for a total of 84.0336 million subscription shares at a subscription price of HK$2.38 per subscription share.
CANBRIDGE-B (01228) announced that on February 15, 2026, the Company entered into a subscription agreement with the subscriber, whereby the Company has conditionally agreed to issue, and the subscriber has conditionally agreed to subscribe for, a total of 84.0336 million subscription shares at a subscription price of HK$2.38 per subscription share.
The subscription price of HK$2.38 per subscription share represents a discount of approximately 14.70% to the closing price of HK$2.79 per share on the Stock Exchange of Hong Kong on February 13, 2026 (the last trading day).
The total amount of funds raised from the subscription will be approximately HK$200 million, and after deducting the related expenses incurred in connection with the subscription, the Company estimates that the net funds receivable from the subscription will be approximately HK$199 million. The net issue price per subscription share is HK$2.37. The Company intends to use the net proceeds from the subscription for operating capital and maintenance of commercialized products, research and development expenses for existing product lines, and settlement of the trade payables of the Group.
Related Articles

The Pacific Shipping (02343): Dr. Harry Pang and Angad Banga appointed as non-executive directors.

ZTO EXPRESS-W (02057) spent 15.12 million US dollars on February 13th to repurchase 612,400 shares.

CSTONE PHARMA-B(02616): The Phase II clinical trial application for CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) has been approved by the US FDA.
The Pacific Shipping (02343): Dr. Harry Pang and Angad Banga appointed as non-executive directors.

ZTO EXPRESS-W (02057) spent 15.12 million US dollars on February 13th to repurchase 612,400 shares.

CSTONE PHARMA-B(02616): The Phase II clinical trial application for CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) has been approved by the US FDA.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


